WallStSmart

20/20 Biolabs, Inc. Common Stock (AIDX)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 1736843% more annual revenue ($35.48B vs $2.04M). MDT leads profitability with a 13.0% profit margin vs -1.6%. MDT earns a higher WallStSmart Score of 56/100 (C).

AIDX

Avoid

18

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 5.0Quality: 5.0

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AIDX.

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIDX1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
15.8%8/10

15.8% revenue growth

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

AIDX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.59M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Price/BookValuation
164.0x2/10

Trading at 164.0x book value

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : AIDX

The strongest argument for AIDX centers on Revenue Growth. Revenue growth of 15.8% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : AIDX

The primary concerns for AIDX are EPS Growth, Market Cap, Return on Equity.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

AIDX profiles as a growth stock while MDT is a value play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.73 — expect wider price swings.

AIDX is growing revenue faster at 15.8% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 18/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

20/20 Biolabs, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

20/20 Biolabs, Inc. (ticker: AIDX) is a biotechnology company focused on providing innovative solutions for genomic research and diagnostics. The company specializes in delivering advanced laboratory services that enhance the accuracy and efficiency of genetic testing, catering to both clinical and research markets. With a commitment to leveraging cutting-edge technologies, 20/20 Biolabs aims to redefine the standards of molecular diagnostics and contribute significantly to the advancement of personalized medicine. As the demand for genomic data continues to rise, the company's strategic initiatives position it well for growth in this rapidly evolving sector.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?